ArticleArchives of medical science : AMS2015
Lipid-lowering therapy in older persons.
Article in Archives of medical science : AMS, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Drug Therapy of Dyslipidemia in the Elderly.Drugs & aging · 2019Review
- Practice setting and secondary prevention of coronary artery disease.Archives of medical science : AMS · 2018Article
- The impact of hyperglycemia and hyperlipidemia on plasma P-selectin and platelet markers after ischemic stroke.Archives of medical science : AMS · 2017Article
- Effect of evacetrapib on cardiovascular outcomes in patients with high-risk cardiovascular disease.Journal of thoracic disease · 2017Article
- A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study.Archives of medical science : AMS · 2017Article
- Discussion around statin discontinuation in older adults and patients with wasting diseases.Journal of cachexia, sarcopenia and muscle · 2016Article
- Molecular mechanisms of statin intolerance.Archives of medical science : AMS · 2016Article
- Lipid-lowering and anti-inflammatory effects of omega 3 ethyl esters and krill oil: a randomized, cross-over, clinical trial.Archives of medical science : AMS · 2016Article
- Update of treatment of heart failure with reduction of left ventricular ejection fraction.Archives of medical sciences. Atherosclerotic diseases · 2016Article
- Lipids, blood pressure and kidney update 2015.Lipids in health and disease · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous randomized, double-blind, placebo-controlled studies and observational studies have shown that statins reduce mortality and major cardiovascular events in older high-risk persons with hypercholesterolemia. The Heart Protection Study showed that statins reduced mortality and major cardiovascular events in high-risk persons regardless of the initial level of serum lipids, age, or gender. The updated National Cholesterol Education Program III guidelines state that in very high-risk persons, a serum low-density lipoprotein (LDL) cholesterol level of < 70 mg/dl (1.8 mmol/l) is a reasonable clinical strategy for moderately high-risk persons (2 or more risk factors and a 10-year risk for coronary artery disease of 10% to 20%), and the serum LDL cholesterol should be reduced to < 100 mg/dl (2.6 mmol/l). When LDL cholesterol-lowering drug therapy is used to treat high-risk persons or moderately high-risk persons, the serum LDL cholesterol should be reduced by at least 30% to 40%. The serum LDL cholesterol should be decreased to less than 160 mg/dl in persons at low risk for cardiovascular disease. Addition of other lipid-lowering drugs to statin therapy has not been demonstrated to further reduce cardiovascular events and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.